|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Electric field detection and ranging of aircraft显示文摘 | Trinks H | 1982 | IEEE on Aerospace and Electric System1982，18，3： | 1 |
| 2 | Construction and initial characterization of a mouse-human chimeric anti-TNF antibody显示文摘 | Knight DW Trink H Le J | 1993 | Mol lmmunol1993，30，： | 1 |
| 3 | Electric charging and discharging processes of moving projectiles显示文摘 | Terhaseborg J L Trinks H | 1980 | IEEE Transactions on Aerospace and Electronic Systems1980，16，2： | 1 |
| 4 | Application of charging effects:ranging of aircraft显示文摘 | Trinks H | 1982 | IEEE Transactions on Aerospace Electronic System1982，18，1： | 1 |
| 5 | Electric field detection and ranging of air- craft显示文摘 | TRINKS H | 1982 | IEEE on Aerospace and Electric system1982，18，3： | 1 |
| 6 | Electric field detection and ranging of aircraft显示文摘 | Trinks H | 1982 | IEEE on Aerospace and Electric System1982，18，： | 1 |
| 7 | IEEE TRANSACTIONS ON AEROSPACE AND ELECTRONIC SYSTEMS显示文摘 | TRINKS H | 1980 | AES-16(2)1980，16，2： | 1 |
| 8 | The pan-ErbB receptor tyrosine kinase inhibitor eanertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo 显示文摘 | Djerf Severinsson EA Trinks C Gr6en H | 2011 | Biochem Biophys Res Commun2011，414，3： | 1 |
| 9 | Electric Charging and Dis- charging Processes of Moving Projectiles显示文摘 | TERHASEBORG J L TRINKS H | 1980 | IEEE Transac- tions on Aerospace and Electronic Systems1980，，2： | 1 |
| 10 | Electric charging and discharging processes of moving projectiles显示文摘 | Terhaseborg J L Trinks H | 1980 | IEEE Transactions on Aerospace and Electronic Systems1980，16，2： | 1 |
| 11 | 4,5-Bis(4-fluoroanilino) phthalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity 显示文摘 | Buchdunger E Mett H Trinks U | 1995 | Clin Cancer Res1995，1，8： | 1 |
| 12 | 4, 5-Dis(4-fluoroanilino) phthalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity显示文摘 | Buchdunger E Mett H Trinks U | 1995 | Clin Cancer Res1995，1，8： | 1 |
| 13 | Application of charging effects ranging of aircraft显示文摘 | Trinks H | 1982 | IEEE Trans on Aerospace Electronic System1982，36，3： | 1 |
| 14 | Electric field detection and ranging of aircraft显示文摘 | Trinks H | 1982 | IEEE on Aerospace and Electric System1982，18，： | 1 |
| 15 | Electric field detection and ranging of aircraft 显示文摘 | | 1982 | IEEE on Aerospace and Electric System1982，，3： | 1 |
| 16 | Construction and initial characterization of a mouse-human chimeric anti-TNF antibody显示文摘 | Knight D W Trink H Le J | 1993 | Mol Immunol1993，30，： | 1 |
| 17 | Electric field detection and ranging of aircraft显示文摘 | Trinks H | 1982 | IEEE on Aerospace and Electronic System1982，18，： | 1 |
| 18 | Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3显示文摘AIM: To evaluate pre-treatment factors associated with sustained virological response(SVR) in patients with hepatitis C virus(HCV) genotype 3 treated with peginterferon and ribavirin(RBV). METHODS: We retrospectively analyzed treatment naive, mono-infected HCV genotype 3 patients treated with peginterferon and RBV. Exclusion criteria included presence of other liver disease, alcohol consumption and African American or Asian ethnicity. The variables collected and compared between patients who achieved an SVR and patients who did not were as follows: gender, age, fibrosis stage, diabetes, body mass index,steatosis, INFL3 polymorphism, pre-treatment HCVRNA, type of peginterferon, RBV dose and adherence. RESULTS: A total of 107 patients treated between June, 2004 and March, 2013 were included. Mean treatment duration was 25.1(± 1.8) wk. Overall, 58%(62/107) of the patients achieved an SVR and 42%(45/107) did not. In the multivariate logistic regression analysis, pre-treatment HCV-RNA ≥ 600000 UI/m L(OR = 0.375, 95%CI: 0.153-0.919, P = 0.032) and advanced fibrosis(OR = 0.278, 95%CI: 0.113-0.684,P = 0.005) were significantly associated with low SVR rates. In patients with pre-treatment HCV-RNA ≥600000 UI/m L and advanced fibrosis, the probability of achieving an SVR was 29%(95%CI: 13.1-45.2).In patients with pre-treatment HCV-RNA < 600000UI/m L and mild to moderate fibrosis, the probability of achieving an SVR was 81%(95%CI: 68.8-93.4).CONCLUSION: In patients with HCV genotype 3infections the presence of advance fibrosis and high pre-treatment viral load might be associated with poor response to peginterferon plus RBV. These patients could benefit the most from new direct antiviral agentsbased regimes. | Sebastian Marciano Silvia M Borzi Melisa Dirchwolf Ezequiel Ridruejo Manuel Mendizabal Fernando Bessone Maria E Sirotinsky Diego H Giunta Julieta Trinks Pablo A Olivera Omar A Galdame Marcelo O Silva Hugo A Fainboim Adrian C Gadano | 2015 | World Journal of Hepatology2015，7，4： | 1 |
| 19 | Electric field detection and ranging of aircraft 显示文摘 | Trinks H | 1982 | IEEE on Aerospace and Electronic System1982，18，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员